Ads
related to: why is 23 and me wrong on my computer today and give me 2 years
Search results
Results From The WOW.Com Content Network
Despite operating for nearly two decades without profit, 23andMe went public in 2021 and reached a $6 billion valuation. The company's stocks were priced at $11.13 a share, but they've fallen ...
In October 2023, Wired reported that a sample of data points from 23andMe accounts were exposed on BreachForums, a black-hat hacking crime forum. [1]23andMe confirmed to TechCrunch that because of an opt-in feature that allows DNA-related relatives to contact each other, the true number of people exposed was 6.9 million, nearly half of 23andMe’s 14 million reported customers.
On 5 January 1975, the 12-bit field that had been used for dates in the TOPS-10 operating system for DEC PDP-10 computers overflowed, in a bug known as "DATE75". The field value was calculated by taking the number of years since 1964, multiplying by 12, adding the number of months since January, multiplying by 31, and adding the number of days since the start of the month; putting 2 12 − 1 ...
(Reuters) - 23andMe will pay $30 million and provide three years of security monitoring to settle a lawsuit accusing the genetics testing company of failing to protect the privacy of 6.9 million ...
A class action lawsuit, resignations, layoffs, and other problems have plagued 23andMe. The company's issues have led to consumer concerns about how it handles genealogy data.
The leap year problem (also known as the leap year bug or the leap day bug) is a problem for both digital (computer-related) and non-digital documentation and data storage situations which results from errors in the calculation of which years are leap years, or from manipulating dates without regard to the difference between leap years and common years.
The year 2038 problem (also known as Y2038, [1] Y2K38, Y2K38 superbug or the Epochalypse [2] [3]) is a time computing problem that leaves some computer systems unable to represent times after 03:14:07 UTC on 19 January 2038.
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring ...